Latest

1 story

Hide weekly roundups

Wednesday, September 2

NervGen registers Phase 3 RESTORE trial of NVG-291 in chronic spinal cord injury

Trial updateNervGen Pharma NVG-291

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.